Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov;33(6):e14443.
doi: 10.1111/dth.14443. Epub 2020 Nov 15.

CD147 as a novel receptor in the pathogenesis of SARS-CoV-2: Is there any correlation with the risk of COVID-19 in dermatological diseases?

Mohammad Reza Pourani  1 , Fahimeh Abdollahimajd  1   2
Affiliations
Comment

CD147 as a novel receptor in the pathogenesis of SARS-CoV-2: Is there any correlation with the risk of COVID-19 in dermatological diseases?

Mohammad Reza Pourani et al. Dermatol Ther. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Comment on

References

    1. Cavezzi A, Troiani E, Corrao S. COVID‐19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020;10:1271. - PMC - PubMed
    1. Ulrich H, Pillat MM. CD147 as a target for COVID‐19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020;1‐7. 10.1007/s12015-020-09976-7. [Epub online ahead of print]. - DOI - PMC - PubMed
    1. Rodrigues‐Diez RR, Tejera‐Muñoz A, Marquez‐Exposito L, et al. Statins: could an old friend help the fight against COVID‐19? Br J Pharmacol. 2020;177:4873‐4886. - PMC - PubMed
    1. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26 and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors. Allergy. 2020;75(11):2829‐2845. - PMC - PubMed
    1. Bian H, Zheng Z‐H, Wei D, et al. Meplazumab treats COVID‐19 pneumonia: an open‐labelled, concurrent controlled add‐on clinical trial. MedRxiv. 2020. 10.1101/2020.03.21.20040691. [Epub online ahead of print]. - DOI

Substances